Eli Lilly lands in Boston the week of the ADA Scientific Sessions

Eli Lilly flew from Wellsville, New York, to Boston on June 15, a 55-minute hop in its Gulfstream G500, N308EL. The brief trip came days after the company’s top executives and scientists presented at the American Diabetes Association’s 86th Scientific Sessions, held this year in Boston, per the conference schedule.

At the ADA meeting, Eli Lilly detailed Phase 3 results for its oral GLP-1 Foundayo (orforglipron), which outperformed oral semaglutide in head-to-head trials for type 2 diabetes, and for retatrutide, a triple-hormone agonist that drove average weight loss of 28% in obesity patients, as reported by CNBC and Morningstar. The company is preparing for Medicare coverage of its GLP-1 drugs starting July 1, a shift that could expand access to millions of seniors.

The flight to Boston follows a pattern of Eli Lilly’s G500s moving between Indianapolis, clinical trial sites, and major medical conferences. Earlier this month, the same aircraft visited Florida and Texas, likely supporting the company’s expanding obesity franchise and dealmaking spree, which has already topped $10 billion in upfront spending this year, per CNBC.